IDEXX Laboratories (NASDAQ:IDXX) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a hold rating to a buy rating and set a $274.00 price target on the stock in a research note on Thursday. Piper Jaffray Companies boosted their price target on shares of IDEXX Laboratories to $236.00 and gave the stock an overweight rating in a research note on Wednesday. Canaccord Genuity reiterated a positive rating and set a $215.00 price target on shares of IDEXX Laboratories in a research note on Monday, May 7th. ValuEngine upgraded shares of IDEXX Laboratories from a hold rating to a buy rating in a research note on Wednesday, May 2nd. Finally, BidaskClub lowered shares of IDEXX Laboratories from a strong-buy rating to a buy rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of Buy and an average price target of $239.33.
Get IDEXX Laboratories alerts:IDXX stock traded up $3.07 during trading on Thursday, reaching $239.22. 25,571 shares of the company were exchanged, compared to its average volume of 404,681. The company has a market cap of $21.28 billion, a P/E ratio of 72.93, a P/E/G ratio of 2.24 and a beta of 0.69. IDEXX Laboratories has a 52-week low of $146.09 and a 52-week high of $252.49. The company has a current ratio of 0.96, a quick ratio of 0.72 and a debt-to-equity ratio of -12.43.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.06. The firm had revenue of $580.75 million for the quarter, compared to the consensus estimate of $574.68 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The firm’s revenue was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.87 earnings per share. equities research analysts expect that IDEXX Laboratories will post 4.17 earnings per share for the current year.
In related news, VP Jacqueline Studer sold 475 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $209.98, for a total transaction of $99,740.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William T. End sold 9,470 shares of the business’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $208.36, for a total transaction of $1,973,169.20. Following the sale, the director now directly owns 31,786 shares in the company, valued at approximately $6,622,930.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,571 shares of company stock worth $2,405,215. 2.56% of the stock is owned by insiders.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: Trading Strategy Examples and Plans
No comments:
Post a Comment